<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Chronic Kidney Disease | Family Medicine Reference</title>
  <style>
    body {
      font-family: "Segoe UI", Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #212529;
      line-height: 1.6;
      margin: 40px;
    }
    h1, h2, h3 {
      color: #004085;
    }
    section {
      background: #ffffff;
      border-radius: 8px;
      box-shadow: 0 2px 5px rgba(0,0,0,0.1);
      padding: 25px;
      margin-bottom: 20px;
    }
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 10px 0;
    }
    th, td {
      border: 1px solid #dee2e6;
      padding: 10px;
      text-align: left;
    }
    th {
      background-color: #e9ecef;
    }
    .source {
      font-size: 0.9em;
      color: #555;
    }
    a {
      color: #0069d9;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
  </style>
  <script src="theme.js"></script>
</head>
<body>

  <h1>Chronic Kidney Disease (CKD)</h1>

  <section>
    <h2>Definition</h2>
    <p>
      Chronic kidney disease is defined as an abnormality of kidney structure or function 
      that persists for <strong>more than 3 months</strong> and affects overall health.
    </p>
  </section>

  <section>
    <h2>Common Causes</h2>
    <ul>
      <li>Diabetes mellitus</li>
      <li>Hypertension</li>
      <li>Chronic glomerulonephritis</li>
      <li>Polycystic kidney disease</li>
      <li>Prolonged obstruction or recurrent infections</li>
    </ul>
  </section>

  <section>
    <h2>Pathophysiology</h2>
    <p>
      Progressive nephron loss leads to compensatory hyperfiltration in remaining nephrons,
      causing further damage, glomerulosclerosis, and tubular atrophy. 
      The decline in GFR results in fluid, electrolyte, and metabolic disturbances.
    </p>
  </section>

  <section>
    <h2>Clinical Presentation</h2>
    <ul>
      <li>Asymptomatic in early stages</li>
      <li>Fatigue, pruritus, anorexia in advanced stages</li>
      <li>Signs of fluid overload: peripheral edema, dyspnea</li>
      <li>Uremic symptoms: confusion, nausea, metallic taste</li>
    </ul>
  </section>

  <section>
    <h2>Diagnostic Evaluation</h2>
    <h3>Screening and Diagnosis</h3>
    <ul>
      <li>Screen high-risk patients (e.g., diabetes, hypertension) annually.</li>
      <li>Diagnosis is based on reduced <strong>eGFR &lt; 60 mL/min/1.73 m²</strong> or markers of kidney damage for &gt;3 months.</li>
    </ul>

    <h3>Laboratory Tests</h3>
    <table>
      <tr><th>Test</th><th>Purpose</th></tr>
      <tr><td>Serum creatinine and eGFR</td><td>Estimate kidney function.</td></tr>
      <tr><td>Urinalysis</td><td>Detect proteinuria or hematuria.</td></tr>
      <tr><td>Urine albumin-to-creatinine ratio (ACR)</td><td>Quantify albuminuria.</td></tr>
      <tr><td>Electrolytes (Na⁺, K⁺, Ca²⁺, phosphate)</td><td>Identify metabolic abnormalities.</td></tr>
      <tr><td>Hemoglobin</td><td>Assess for anemia of CKD.</td></tr>
      <tr><td>Parathyroid hormone (PTH)</td><td>Assess for CKD-mineral and bone disorder.</td></tr>
    </table>

    <h3>Imaging</h3>
    <ul>
      <li>Renal ultrasound: small echogenic kidneys suggest chronic disease.</li>
      <li>CT or MRI if structural abnormality suspected.</li>
    </ul>
  </section>

  <section>
    <h2>Staging of CKD (KDIGO Classification)</h2>
    <table>
      <tr><th>Stage</th><th>eGFR (mL/min/1.73 m²)</th><th>Description</th></tr>
      <tr><td>G1</td><td>≥ 90</td><td>Normal or high with evidence of damage</td></tr>
      <tr><td>G2</td><td>60–89</td><td>Mildly decreased</td></tr>
      <tr><td>G3a</td><td>45–59</td><td>Mild to moderate decrease</td></tr>
      <tr><td>G3b</td><td>30–44</td><td>Moderate to severe decrease</td></tr>
      <tr><td>G4</td><td>15–29</td><td>Severely decreased</td></tr>
      <tr><td>G5</td><td>&lt; 15</td><td>Kidney failure / ESRD</td></tr>
    </table>
  </section>

  <section>
    <h2>Complications</h2>
    <ul>
      <li>Anemia of CKD</li>
      <li>Electrolyte imbalance (hyperkalemia, metabolic acidosis)</li>
      <li>CKD–Mineral and Bone Disorder (CKD-MBD)</li>
      <li>Volume overload and hypertension</li>
      <li>Uremic pericarditis, encephalopathy</li>
      <li>Increased risk of atherosclerotic cardiovascular disease</li>
    </ul>
  </section>

  <section>
    <h2>Management</h2>
    <h3>1. General Principles</h3>
    <ul>
      <li>Treat the underlying cause (e.g., diabetes, hypertension, GN).</li>
      <li>Avoid nephrotoxic agents (NSAIDs, contrast media, aminoglycosides).</li>
      <li>Maintain euvolemia and balanced nutrition.</li>
    </ul>

    <h3>2. Pharmacologic Therapy</h3>
    <ul>
      <li><strong>ACE inhibitors / ARBs:</strong> slow progression by reducing intraglomerular pressure.</li>
      <li><strong>SGLT2 inhibitors:</strong> recommended in diabetics with CKD.</li>
      <li><strong>Statins:</strong> reduce cardiovascular risk.</li>
      <li><strong>Erythropoiesis-stimulating agents (ESAs):</strong> treat anemia when Hb &lt; 10 g/dL.</li>
      <li><strong>Phosphate binders, vitamin D analogues:</strong> manage CKD-MBD.</li>
    </ul>

    <h3>3. Lifestyle and Nutrition</h3>
    <ul>
      <li>Low-sodium, low-protein diet (0.6–0.8 g/kg/day if not on dialysis).</li>
      <li>Manage blood pressure to &lt;130/80 mmHg.</li>
      <li>Encourage smoking cessation and regular exercise.</li>
    </ul>

    <h3>4. Renal Replacement Therapy</h3>
    <p>
      Indicated for end-stage renal disease (eGFR &lt; 15 or refractory complications).  
      Options include:
    </p>
    <ul>
      <li>Hemodialysis</li>
      <li>Peritoneal dialysis</li>
      <li>Renal transplantation</li>
    </ul>
  </section>

  <section>
    <h2>Monitoring and Follow-up</h2>
    <ul>
      <li>Monitor BP, renal function, and electrolytes regularly.</li>
      <li>Adjust drug doses according to eGFR.</li>
      <li>Screen for cardiovascular risk factors.</li>
    </ul>
  </section>

  <p class="source">
    Source: <a href="https://www.amboss.com/us/knowledge/chronic-kidney-disease?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">
    AMBOSS: Chronic Kidney Disease</a>
  </p>

</body>
</html>
